The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
about
Targeted therapies with companion diagnostics in the management of breast cancer: current perspectivesQuantification of HER family receptors in breast cancerUse of Biomarkers to Guide Decisions on Adjuvant Systemic Therapy for Women With Early-Stage Invasive Breast Cancer: American Society of Clinical Oncology Clinical Practice GuidelineLimitations in predicting PAM50 intrinsic subtype and risk of relapse score with Ki67 in estrogen receptor-positive HER2-negative breast cancer.Late recurrences in early breast cancer: for whom and how long is endocrine therapy beneficial?Selecting postoperative adjuvant systemic therapy for early stage breast cancer: A critical assessment of commercially available gene expression assays.Mutational profiles in triple-negative breast cancer defined by ultradeep multigene sequencing show high rates of PI3K pathway alterations and clinically relevant entity subgroup specific differences.Lack of effect of metformin on mammary carcinogenesis in nondiabetic rat and mouse models.A segregation index combining phenotypic (clinical characteristics) and genotypic (gene expression) biomarkers from a urine sample to triage out patients presenting with hematuria who have a low probability of urothelial carcinomaMolecular characterization and targeted therapeutic approaches in breast cancerDevelopment and verification of the PAM50-based Prosigna breast cancer gene signature assayResponse and survival of breast cancer intrinsic subtypes following multi-agent neoadjuvant chemotherapy.Prognostic Impact of the Combination of Recurrence Score and Quantitative Estrogen Receptor Expression (ESR1) on Predicting Late Distant Recurrence Risk in Estrogen Receptor-Positive Breast Cancer After 5 Years of Tamoxifen: Results From NRG OncologPrognostic value of automated KI67 scoring in breast cancer: a centralised evaluation of 8088 patients from 10 study groups.Diagnostic tests based on gene expression profile in breast cancer: from background to clinical use.Multi-gene classifiers for prediction of recurrence in breast cancer patients.New Molecular Assay for the Proliferation Signature in Mantle Cell Lymphoma Applicable to Formalin-Fixed Paraffin-Embedded Biopsies.Indications for prognostic gene expression profiling in early breast cancer.Cognitive effects of endocrine therapy for breast cancer: keep calm and carry on?Gene-Expression-Based Predictors for Breast Cancer.A 2015 update on predictive molecular pathology and its role in targeted cancer therapy: a review focussing on clinical relevance.St. Gallen/Vienna 2017: A Brief Summary of the Consensus Discussion about Escalation and De-Escalation of Primary Breast Cancer Treatment.Biomarker assessment and molecular testing for prognostication in breast cancer.Identification of novel biomarkers associated with poor patient outcomes in invasive breast carcinoma.Prognostic immune-related gene models for breast cancer: a pooled analysis.Prognostic and predictive investigation of PAM50 intrinsic subtypes in the NCIC CTG MA.21 phase III chemotherapy trial.Cell signaling events differentiate ER-negative subtypes from ER-positive breast cancer.Developing a new generation of breast cancer clinical gene expression testsClinical utility of multigene profiling assays in early-stage breast cancer.Prognostic value of PAM50 and risk of recurrence score in patients with early-stage breast cancer with long-term follow-up.Assessing the Clinical Benefit of Systemic Adjuvant Therapies for Early Breast Cancer.Utility of molecular tools for extended adjuvant endocrine therapy decisions in early breast cancer.Optimal duration of adjuvant endocrine therapy: how to apply the newest data.Comparison of the Performance of 6 Prognostic Signatures for Estrogen Receptor-Positive Breast Cancer: A Secondary Analysis of a Randomized Clinical Trial.Extended Adjuvant Endocrine Therapy for Postmenopausal Women: Treating Many to Benefit a Few.[Molecular pathology for breast cancer: Importance of the gene expression profile].Prognostic & predictive factors for planning adjuvant chemotherapy of early-stage breast cancer.Challenges in using liquid biopsies for gene expression profiling.Clinical application and utility of genomic assays in early-stage breast cancer: key lessons learned to date.Optimal management of luminal breast cancer: how much endocrine therapy is long enough?
P2860
Q26768119-1554ABF0-66DD-46E5-A888-BE7B0FF1F86EQ27015506-D33976A9-08F3-4FF2-97EB-C9E938D89660Q28079118-0817E5CC-0260-4B19-A767-285A9FE43254Q33591751-66EE0A7F-2523-45A6-81BB-6504895C79E6Q33684843-AB3E733B-0D6C-4042-8489-217435F19A62Q33834198-0A842FDB-F51E-4BFA-98DB-CCF8758ED23FQ34654793-D319649A-C30B-4CC4-B10F-07B528D69263Q35163721-0D7EE131-89BB-4DF7-AC28-06541D41F940Q35341492-BC231A9F-2D4C-4EF8-848C-9E69F3DF476EQ35530143-71EE0D53-FE30-42D1-93B8-D80B835834D0Q35752868-F532B16F-ED57-4425-93BC-62D0F8022780Q36383626-C5FEC006-5E9E-46D8-936B-FE00B5F8B9E9Q37169337-CF91185E-4197-49F5-B7F2-A05C51984228Q37350137-0B8A5326-36B4-4BC0-9C15-1F148E84AD2FQ38232507-80B7BF14-B259-4BFE-8B83-2F65C8CFC511Q38362985-FD65E697-CB5D-4677-8F24-2D3B0F788A41Q38375603-25BDE852-69B7-469B-88AF-491C12214175Q38451798-14042DD7-3674-4C85-BE32-2F49D11D046DQ38551397-C8AE0786-BC9B-411A-B100-565B07C32691Q38555220-461BFF5D-0865-4F99-9675-D768161CFDD1Q38584379-A5EF5207-DA0B-4CA1-8555-879734C943FAQ38676979-DB179517-FF24-40E8-8E4B-FB644FFDB6BCQ38696790-5151C652-0319-42D4-9FE2-135910963F99Q39532008-A77795FA-CED2-4EBB-A0C0-4E638A8540E6Q42001306-027F92AF-41CD-4C08-92CA-D7B0172119FDQ42470916-EBB212DC-F8EF-4B21-9462-A2BCAFF2A105Q42474658-BEAE2E09-D42F-4C9E-B7BE-8C2F4A7908DAQ42737349-9DE57007-826F-4FC7-B77B-7A2CE0E5D118Q47094168-38B4D226-D41C-4E68-952C-C304EEF7D131Q47122813-1D04377C-E9E3-46C5-9F22-5C648BECA671Q47138534-B7D0A950-250B-40BA-AEC2-8722D2AD0F4AQ47821919-1D88851D-7D9B-431C-8979-7C5662A94857Q49177338-CE729C80-6C0D-47EE-BF44-AEC53365C4EFQ49951544-AE34DC7B-86CE-42A2-90E5-1FDCFBC72E75Q50042351-60EC94A2-3F29-421A-88DF-9DD1490148FBQ52868166-F3F1D037-B1DE-4CB3-A992-AE87C35D79E6Q54495437-9FE683D0-285F-43DF-9ACD-EF742B7A071FQ55078140-C342CCF5-C4F6-4B3B-8E12-615AF91B9163Q55334991-7C480C9F-F269-4FD4-BD7C-495220D0054FQ55424072-5B1AB4B3-CC0A-49F7-BE22-7CA22D76F29D
P2860
The PAM50 risk-of-recurrence score predicts risk for late distant recurrence after endocrine therapy in postmenopausal women with endocrine-responsive early breast cancer.
description
2014 nî lūn-bûn
@nan
2014年の論文
@ja
2014年学术文章
@wuu
2014年学术文章
@zh
2014年学术文章
@zh-cn
2014年学术文章
@zh-hans
2014年学术文章
@zh-my
2014年学术文章
@zh-sg
2014年學術文章
@yue
2014年學術文章
@zh-hant
name
The PAM50 risk-of-recurrence s ...... esponsive early breast cancer.
@en
The PAM50 risk-of-recurrence s ...... esponsive early breast cancer.
@nl
type
label
The PAM50 risk-of-recurrence s ...... esponsive early breast cancer.
@en
The PAM50 risk-of-recurrence s ...... esponsive early breast cancer.
@nl
prefLabel
The PAM50 risk-of-recurrence s ...... esponsive early breast cancer.
@en
The PAM50 risk-of-recurrence s ...... esponsive early breast cancer.
@nl
P2093
P1476
The PAM50 risk-of-recurrence s ...... esponsive early breast cancer.
@en
P2093
Austrian Breast and Colorectal Cancer Study Group
Brigitte Mlineritsch
Carl Schaper
Christian F Singer
Christian Fesl
Christine Gruber-Rossipal
Elisabeth Müller-Holzner
Harald Trapl
Herbert Stöger
J Wayne Cowens
P304
P356
10.1158/1078-0432.CCR-13-1845
P407
P577
2014-02-11T00:00:00Z